NEW YORK, April 1, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational
Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND),
Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc.
(NASDAQ: NVDQ). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
Cytokinetics, Inc. Analyst Notes
On March 27, 2014, Cytokinetics,
Inc. (Cytokinetics) announced the initiation of an additional Phase
I clinical trial of CK-2127107. Cytokinetics informed that the
trail, called CY 5012, aims to assess the safety, tolerability, and
pharmacokinetics of CK-2127107 following multiple ascending doses
in healthy volunteers. The Company informed that the initiation of
the clinical trial will result in a $2.0
million milestone payment from Astellas Pharma Inc.
(Astellas) to Cytokinetics under the terms of the collaboration
between the Companies established in June
2013. Commenting on the trial, Fady Malik, MD, PhD, Senior
Vice President of Research and Early Development at Cytokinetics,
stated, "This multi-dose clinical trial of CK-2127107 is another in
the series of Phase I trials that Cytokinetics is conducting on
behalf of the collaboration. These studies along with other Phase
II readiness activities will inform the potential progression of CK
2127107 into a Phase II development program focused on
non-neuromuscular indications." The full analyst notes on
Cytokinetics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04012014/CYTK/report.pdf
--
Quintiles Transnational Holdings, Inc. Analyst
Notes
On March 27, 2014, Quintiles
Transnational Holdings, Inc. (Quintiles) announced the appointment
of Stella Blackburn, M.B.B.S to the
position of Vice President and Global Head of Risk Management for
the Company's Real-World & Late Phase Research group. The
Company stated that in this role, Dr. Blackburn will lead the
group's risk management efforts in North
America, European Union, and Asia-Pacific. Quintiles informed that prior to
joining the Company, Dr. Blackburn was Risk Management Development
and Scientific Lead for the European Medicines AgencyThe full
analyst notes on Quintiles Transnational Holdings, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04012014/Q/report.pdf
--
Kindred Healthcare, Inc. Analyst Notes
On March 26, 2014, Kindred
Healthcare, Inc. (Kindred) announced the pricing of its previously
announced offering of $500.0 million
aggregate principal amount of 6.375% senior notes due 2022 at an
issue price of 100%. The Company informed that it anticipates the
closing of the offering on April 9,
2014. Kindred added that it intends to use the net proceeds
from the sale of the notes and borrowings under certain senior
secured credit facilities to redeem and repurchase its outstanding
$550 million of existing 8.25% senior
notes due 2019. The full analyst notes on Kindred Healthcare, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04012014/KND/report.pdf
--
Volcano Corporation Analyst Notes
On March 19, 2014, Volcano
Corporation (Volcano) announced that it has received FDA clearance
for its proprietary instant wave-Free Ratio™ or iFR® Modality. The
Company informed that the iFR Modality is currently installed on
over 300 systems around the world, mainly in Europe and Japan. Volcano stated that the FDA Clearance
allows 90% of the Company's worldwide installed base of
multi-modality systems to be upgraded. According to Volcano, the
iFR® Modality is used most efficiently with the Company's
recently-introduced Verrata™ Pressure Guide Wire. Commenting on the
clearance, Joe Burnett, Executive
Vice President and General Manager of the FM Business at Volcano,
stated, "We are extremely excited that both the iFR Modality and
Verrata can now be made available to clinicians here in
the United States, as the two
tools are designed to be used together. In Europe, where we are now seeing how physicians
use the two technologies alongside FFR, the feedback has been very
positive." The full analyst notes on Volcano Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/04012014/VOLC/report.pdf
--
Novadaq Technologies, Inc. Analyst Notes
On March 25, 2014, Novadaq
Technologies, Inc. (Novadaq) announced that it will be
participating at the 13th Annual Needham Healthcare
Conference. The Company stated that its Vice President of Corporate
Development & Investor Relations, David
Martin, is scheduled to present Novadaq's corporate overview
on April 8, 2014 at 4:20 p.m. ET at the Westin Grand Central Hotel in
New York. Novadaq added that the
presentation will be webcast live and will also be archived for 90
days on the Company website. The full analyst notes on Novadaq
Technologies, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04012014/NVDQ/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review